Resources
141 Results (showing 11 - 20)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 3/25/2021 (updated 4/5/2024)
Integrating Health Promotion for People Who Inject Drugs (PWID) Into Opioid Use Disorder (OUD) Services
The workshop will present strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session will focus on communication skills, assessment techniques, and building motivation among PWID to make healthier choices. The presenter will look at programmatic and clinical-level integration strategies and offer participants an opportunity to assess current service delivery models and develop a plan to enhance care.
Posted 3/25/2021 (updated 4/5/2024)
State and Regional Focused Presentations: State Substance Use Prevention Systems and the National Prevention Network
Presenters will review the structure and function of state substance use prevention systems, describe the role and activities of the National Prevention Network, and highlight rural prevention initiatives.
Posted 3/25/2021 (updated 4/5/2024)
Federal Resources: A Virtual Tour
Presenters will review resources available to rural grantees through their respective organizations.
Christina Mead, PharmD, Regional Pharmacy Consultant, U.S. Public Health Service, U.S. Department of Health and Human Services/HRSA/Office of Regional Operations
Kristin Martinsen, MPA, Director, Hospital State Division, FORHP, HRSA
Betty-Ann Bryce, JD, MPA, Special Advisor for Rural Affairs, Office of National Drug Control Policy
Humberto Carvalho, MPH, Grants Project Manager, Substance Abuse and Mental Health Services Administration
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 3/10/2021 (updated 4/5/2024)
There are safe ways to dispose of syringes you find on the ground. Sharing injection drug equipment can transmit infections, but there is little risk to someone who is accidentally poked or scratched by a discarded syringe.
Below you'll find information on how to pick them up, where to drop them off, and ways to get involved in cleaning up your neighborhood.
Posted 3/2/2021 (updated 4/5/2024)
Posted 2/17/2021 (updated 4/4/2024)
This packet presents you with the tools, materials and resources necessary to kick off grant activities quickly and efficiently.
Posted 1/27/2021 (updated 4/4/2024)
The current study examined the accuracy of sensory discernment strategies by measuring study participants’ descriptions of the last opioid injected and checked with a fentanyl test strip (FTS) by that test's positive/negative result. The primary objective was to determine associations between FTS results and descriptions of the illi it opioid's physical appearance and physiological effects.
Posted 1/20/2021 (updated 4/4/2024)
People who use drugs (PWUD) in the U.S. experience disproportionate adverse health outcomes and mortality as compared with the population as a whole (Lake & Kennedy, 2016; Reisinger, Pratt, Shoenborn, & Druss, 2017). Similar health outcomes have been reported elsewhere, for example in the UK (Neale, 2004), and across 8 other European countries (Bargagli et al., 2006). In the U.S. health outcomes among PWUD are intensified by the overdose pandemic, epidemic rates of HIV, hepatitis A and C, skin and soft tissue infections (CDC Centers for Disease Control and Prevention, 2020; Hagen, Thiede, & Des Jarlais, 2005; Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019), and by structural barriers thwarting health access and utilization.